A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
Suder, A, Ang, J.E, Kyle, F, Harris, D, Rudman, S, Kristeleit, R, Solca, F, Uttenreuther-Fischer, M, Pemberton, K, Pelling, K, Schnell, D, de Bono, J, Spicer, J
Published in European journal of cancer (1990) (01.11.2015)
Published in European journal of cancer (1990) (01.11.2015)
Get full text
Journal Article
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
Vermorken, J.B., Rottey, S., Ehrnrooth, E., Pelling, K., Lahogue, A., Wind, S., Machiels, J.-P.
Published in Annals of oncology (01.05.2013)
Published in Annals of oncology (01.05.2013)
Get full text
Journal Article
1204 ORAL A Phase lb Open-label Study to Assess Continuous Oral Treatment With Afatinib (BIBW 2992) in Combination With Two Chemotherapy Regimens – Cisplatin Plus Paclitaxel, and Cisplatin Plus 5-fluorouracil in Patients, With Advanced Solid Tumours
Vermorken, J, Rottey, S, Ehrnrooth, E, Pelling, K, Lahogue, A, Machiels, J
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
P7 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
Crestani, B, Ogura, T, Pelling, K, Coeck, C, Quaresma, M, Kreuter, M, Kaye, M
Published in Thorax (01.12.2015)
Published in Thorax (01.12.2015)
Get full text
Journal Article
A15 THE LONG AND WINDING ROAD TO IPF TREATMENT: EXPANDED ANALYSES OF PIRFENIDONE AND NINTEDANIB: Safety And Tolerability Of Nintedanib In Patients With Ipf: Interim Analysis From An Open-Label Extension Of The Inpulsis® Trials (inpulsis®-On)
Crestani, B, Ogura, T, Pelling, K, Quaresma, M, Coeck, C, Kaye, M
Published in American journal of respiratory and critical care medicine (01.01.2015)
Get full text
Published in American journal of respiratory and critical care medicine (01.01.2015)
Journal Article
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
Kreuter, M, Crestani, B, Ogura, T, Pelling, K, Coeck, C, Quaresma, M, Kaye, M
Published in Pneumologie (09.02.2016)
Published in Pneumologie (09.02.2016)
Get full text
Conference Proceeding
464P - A Phase I Study of Daily Afatinib, an Irreversible Erbb Family Blocker, Combined With Weekly Paclitaxel and 2-Weekly Bevacizumab in Patients with Advanced Solid Tumours
Enting, D., Ang, J.E., O'Hanlon-Brown, C., Kristeleit, R., Uttenreuther-Fischer, M., Pemberton, K., Pelling, K., Schnell, D., de Bono, J.S., Spicer, J.
Published in Annals of oncology (01.09.2012)
Published in Annals of oncology (01.09.2012)
Get full text
Journal Article
A Phase I Study of Daily Afatinib, an Irreversible Erbb Family Blocker, Combined With Weekly Paclitaxel and 2-Weekly Bevacizumab in Patients with Advanced Solid Tumours
Enting, D., Ang, J.E., O'Hanlon-Brown, C., Kristeleit, R., Uttenreuther-Fischer, M., Pemberton, K., Pelling, K., Schnell, D., de Bono, J.S., Spicer, J.
Published in Annals of oncology (01.09.2012)
Published in Annals of oncology (01.09.2012)
Get full text
Journal Article
Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors
Vermorken, J. B., Machiels, J. H., Rottey, S., Thurm, H. C., Pelling, K., Lahogue, A.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article